Use of the tumor necrosis factor-blockers for Crohn's disease

doi:10.3748/wjg.v18.i35.4823

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 35

This Article

(0)

(9597)

(21)

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Guidelines for Clinical Practice

World J Gastroenterol. Sep 21, 2012; 18(35): 4823-4854
Published online Sep 21, 2012. doi: 10.3748/wjg.v18.i35.4823

Table 26 Natural history of Crohn’s disease and ulcerative colitis %

Natural history
UC		CD¹
Remission at any point in time	50	Relapse	10-30
Overall intermittent course	90	Low activity	15-20
Remission: 3-7 yr after diagnosis	25	Remission	55-65
Yearly relapse	18	Chronic active	13-20
Intermittent relapse	51	Chronic intermittent	67-73
		Remission for 10 yr	13
10 yr colectomy rate	10	Surgery by 20 yr	> 75
Change in site of UC over 25 yr		Change in behavior
LC→ C	50	NSNF → S	27
C → LC	75	NSNF → F	29

¹Course 1 year after diagnosis. C: Entire colon; LC: Left colon; S: Structuring; F: Fistulising; NSNF: Non-stricturing, non-fistulizing; UC: Ulcerative colitis; CD: Crohn's disease.

Full Size Table

Citation: Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854
URL: https://www.wjgnet.com/1007-9327/full/v18/i35/4823.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i35.4823

Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854 [PMID: 23002356 DOI: 10.3748/wjg.v18.i35.4823]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.